nature research

Corresponding author(s): Stuart H. Orkin

Last updated by author(s): Jan 14, 2021

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	firmed
	\square	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes		A description of all covariates tested
\boxtimes		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable</i> .
\boxtimes		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code Raw data of high throughput sequencing were collect on Illumina Nextseq or Novaseq platforms with the default factory softwares. Data collection Data analysis For dCas9 and Cas9 dense perturbation analysis, these softwares were used: DESeq2, R 4.0.1, CRISPR-SURF 1.0. For ChIP-seq, CUT&RUN, ATAC-seq analysis, FastQC 0.11.9, CUT&RUNTools, MAnorm 1.1.4 and deeptools 2.0 were used. CUT&RUNTools integrates the following softwares: Trimmomatic 0.36, Bowtie 2.2.9, Samtools 1.3.1, Picard 2.8.0, MACS 2.1.1, MEME 4.12.0, Bedops 2.4.30, Bedtools 2.26.0. Statistic analysis of qPCR was carried out with GraphPad Prism 8. For PRO-seq analysis, Cutadapt 1.14, Bowtie 1.2.2, Samtools 1.3.1 were used. Custom scripts were used to quantify signals on each gene (https://github.com/yao-qiuming/Nan NG2020). For quantification of Cas9 editing or base editing efficiency, TIDE 3.2.0 and TIDER 1.0.2 were used. For flow cytometry analysis, FlowJo V10 was used. Western blot was quantified with ImageJ 2.0 Genome tracks were viewed using IGV 2.7.0 Protein Structure was visualized with PyMOL 1.8.6.1

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets

- A list of figures that have associated raw data
- A description of any restrictions on data availability

All raw and processed CRISPR screen, CUT&RUN, ChIP-seq, PRO-seq and ATAC-seq data have been deposited in the NCBI Gene Expression Omnibus under accession number GSE150530.

All unprocessed western blot gels for figure 4a, Extended Data Figures 2a, 4a, c, 5f can be found in Source Data.

Field-specific reporting

 Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

 If sciences
 Behavioural & social sciences

 Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	High throughput experiments including PRO-seq, CUT&RUN were conducted in duplicates as indicated. No additional sample size calculation was performed. Two replicates are commonly used for high throughput sequencing experiments to ensure reproducibility while controlling cost.
Data exclusions	Base edited cells that showed insertion or deletions at the edited sites were considered not qualified and excluded from the downstream analysis in Figures 3c, g. No other data were excluded from analysis.
Replication	Biological replicates were performed and indicated in Figure legends to ensure reproducibility of the key data.
Randomization	Samples were allocated based on genotypes only. There are no covariates and no randomization was required.
Blinding	All the data were generate by machines and do not involve human intervention of values. Therefore no blinding were performed.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems **Methods** Involved in the study Involved in the study n/a n/a Antibodies ChIP-seq Eukaryotic cell lines Flow cytometry \times Palaeontology and archaeology MRI-based neuroimaging \boxtimes Animals and other organisms \boxtimes Human research participants \boxtimes Clinical data

Dual use research of concern

Antibodies

Antibodies used	BCL11A, ab191401, Abcam; NFYA, sc-17753, Santa Cruz Biotechnology; NFYA, ab139402, Abcam; TBP, ab220788, Abcam; α-Flag M2 antibody, F1804, Sigma-Aldrich;C/EBPB, NBP1-46179, NovusBio; C/EBPG, sc-517003, Santa Cruz Biotechnology; CDP, sc-514008, Santa Cruz Biotechnology; NFIA, HPA008884, Sigma-Aldrich; NFIC, A303-123A-T, Bethyl Laboratories; Histone H3, ab24834, Abcam; HbF, MHFH01, Life Technologies.
Validation	Flag M2 antibody was validated by the manufacturer through immunostaining. HbF antibody was validated by flow cytometry (Extended Data Figure 3g).

April 2020

All other antibodies were validated by the manufacturers through western blot to confirm specific recognition of the human antigens. All WB images were shown in manufacturers' websites.

Eukaryotic cell lines

Policy information about <u>cell lines</u>				
Cell line source(s)	HUDEP-2 cells, HUDEP-1 cells were established and shared by Nakamura group at RIKEN, Japan. 293T cells were purchased from ATCC.			
Authentication	These cells were not authenticated.			
Mycoplasma contamination	Cells were confirmed to be negative for Mycoplasma as determined by PCR.			
Commonly misidentified lines (See <u>ICLAC</u> register)	no commonly misidentified lines were used in this study			

ChIP-seq

Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as GEO.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links May remain private before publication.	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150530 token: crmpygswtvipred
Files in database submission	please see below in Methodology-Sequencing depth
Genome browser session (e.g. <u>UCSC</u>)	https://genome.ucsc.edu/s/nanliu/NFY_CUTRUN_for_NG

Methodology

Replicates	two replicates of CUT&RUN were performed for NFYA CUT&RUN or TBP CUT&RUN in CD34+ cells as indicated in the file names by "rep1" and "rep2". One experiment was done for those experiments without labeling "rep".
Sequencing depth	All experiments were sequenced as paired end, with read length of 42 bp each strand. The numbers of total reads and concordantly aligned reads were listed below. (Uniquely mapped reads were not applicable to this project due to the fact that the HBG1 and HBG2 genes are duplicated.)
	NFYA_ChIP_BCLKOHDP2_ctr,37164569,34771514
	NFYA_ChIP_BCLKOHDP2_shNFYA,36723066,34500130
	NFYA_ChIP_HDP1_ctr,42005143,39225567
	NFYA_ChIP_HDP1_shNFYA,50820724,47620992
	NFYA_ChIP_HDP2_ctr,34634556,32575748
	NFYA_ChIP_HDP2_shNFYA,49777590,46855899
	NFYA_CUTRUN_BCLKOdCas9_102_rep1,33495349,30674512
	NFYA_CUTRUN_BCLKOdCas9_102_rep2,15000000,11920433
	NFYA_CUTRUN_BCLKOdCas9_115_rep1,36819206,33553876
	NFYA_CUTRUN_BCLKOdCas9_115_rep2,15000000,12138125
	NFYA_CUTRUN_BCLKOdCas9_124_rep1,38921171,35940594
	NFYA_CUTRUN_BCLKOdCas9_124_rep2,15000000,12697117
	NFYA_CUTRUN_BCLKOdCas9_139_rep1,33681061,30854506
	NFYA_CUTRUN_BCLKOdCas9_139_rep2,15000000,11807286
	NFYA_CUTRUN_BCLKOdCas9_158_rep1,39688300,35082998
	NFYA_CUTRUN_BCLKOdCas9_158_rep2,15000000,9213025
	NFYA_CUTRUN_BCLKOdCas9_197_rep1,41422415,37376825
	NFYA_CUTRUN_BCLKOdCas9_197_rep2,15000000,8202314
	NFYA_CUTRUN_BCLKOdCas9_208_rep1,46242216,42301794
	NFYA_CUTRUN_BCLKOdCas9_208_rep2,15000000,11279120
	NFYA_CUTRUN_BCLKOdCas9_62_rep1,32979815,30333424
	NFYA_CUTRUN_BCLKOdCas9_62_rep2,15000000,12421347
	NFYA_CUTRUN_BCLKOdCas9_AAVS_rep1,30639854,27773935
	NFYA_CUTRUN_BCLKOdCas9_AAVS_rep2,15000000,10369371
	NFYA_CUTRUN_BCLKOHDP2_rep1,43920791,40823178
	NFYA_CUTRUN_BCLKOHDP2_rep2,34270965,29805299
	NFYA_CUTRUN_CD34_AAVS32_rep1,19057148,15307722
	NFYA_CUTRUN_CD34_AAVS32_rep2,14637450,13197549
	NFYA_CUTRUN_CD34_AAVS72_rep2,25988936,22767333
	NFYA_CUTRUN_CD34_KO32_rep1,17456600,15834599
	NFYA_CUTRUN_CD34_KO32_rep2,20485966,19147012
	NFYA_CUTRUN_CD34_KO72_rep2,9283584,8254157
	NFYA_CUTRUN_CD34_shBCL,39674277,34823019

	NFYA_CUTRUN_CD34_shCtr,33222760,28880730
	NFYA_CUTRUN_CD34_shNFYA,47578352,42263166
	NFYA_CUTRUN_cloneA9d,23624493,15919597
	NFYA_CUTRUN_cloneB2p,18004344,9288219
	NFYA_CUTRUN_cloneB6p,14853815,3893985
	NFYA_CUTRUN_cloneB7d,16272000,9493221
	NFYA_CUTRUN_cloneB7p,29818667,16787151
	NFYA_CUTRUN_cloneB8p,24889493,10095503
	NFYA_CUTRUN_cloneC4p,15589029,9744071
	NFYA_CUTRUN_cloneD10d,19563736,11344188
	NFYA_CUTRUN_cloneE11p,10817294,3269153
	NFYA_CUTRUN_cloneE1d,27306601,20014302
	NFYA_CUTRUN_cloneE6p,18850494,13870224
	NFYA_CUTRUN_cloneF11d,19154878,13213573
	NFYA_CUTRUN_cloneG10p,10822717,3922287
	NFYA_CUTRUN_cloneG8d,15036288,7312922
	NFYA_CUTRUN_Cord_CD34,18609228,16381146
	NFYA_CUTRUN_HDP1_rep1,28560486,26192514
	NFYA_CUTRUN_HDP1_rep2,25445084,19593285
	NFYA_CUTRUN_HDP2_rep1,31546932,29406956
	NFYA_CUTRUN_HDP2_rep2,32928500,29206382
	TBP_CUTRUN_CD34_AAVS32_rep1,20255744,17996530
	TBP_CUTRUN_CD34_AAVS32_rep2,16770308,15517167
	TBP_CUTRUN_CD34_AAVS72_rep2,28013959,24829072
	TBP_CUTRUN_CD34_KO32_rep1,21978816,20072549
	TBP_CUTRUN_CD34_KO32_rep2,24492508,22990688
	TBP_CUTRUN_CD34_K072_rep2,20770535,18348659
Antibodies	BCL11A, ab191401, Abcam, for CUT&RUN NFYA, sc-17753, Santa Cruz Biotechnology, for CUT&RUN NFYA, ab139402, Abcam, for
Antibodies	ChIP-seq; TBP, ab220788, Abcam, for CUT&RUN
Peak calling parameters	Bowtie2 was used to align sequences to hg19, and MACS2 was used to call peaks using -f BAMPE -q 0.01 -B -SPMR.
	Duplicates were retained for CUT&RUN analysis due to the fact that pA-MN digestion (like Tn5 transposition) frequently results in the
	same DNA fragments.
Data quality	Raw data was quality checked with FastQC. Low quality reads and unpaired reads were removed by trimmomatic. Additional read
Data quality	through adapters were trimmed with kseq script in CUT&RUNTools.
	נוויטעפר מעמעינייז איביב נוווווויבע אונוי גאבע אבווער ווי בט דמונטוערטטא.
Software	CUT&RUNTools was used to process ChIP-seq and CUT&RUN data. CUT&RUNTools integrates the following softwares: Trimmomatic
	0.36, Bowtie 2.2.9, Samtools 1.3.1, Picard 2.8.0, MACS 2.1.1, MEME, Bedops 2.4.30, Bedtools 2.26.0.

Flow Cytometry

Plots

Confirm that:

 \square The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

 \bigotimes All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	intracellular staining was performed by fixing cells with 0.05% glutaraldehyde (grade II) (Sigma) for 10 min at room temperature. Cells were centrifuged for 5 min at 600x g and then resuspended in 0.1% Triton X-100 (Life Technologies) for 5 min at room temperature for permeabilization. Triton X-100 was diluted with phosphate buffered saline (PBS) with 0.1% BSA and then centrifuged at 600x g for 15 min. Cells were stained with antibodies for HbF (clone HbF-1 with FITC or APC conjugation; Life Technologies) for 20 min in the dark. Cells were washed to remove unbound antibody before flow cytometry.
Instrument	BD Accuri™ C6 Flow Cytometer
Software	Data were collected using built in software in BD Accuri™ C6 Flow Cytometer and analyzed with FlowJo V10
Cell population abundance	10000-50000 cells were analyzed. Dead cells or doublets were excluded with the gating strategy described below.

FSC/SSC was used to exclude dead cells. FSC-A/FSC-H were used to select single cells. FL1-A channel recorded the FITC fluorescence. Positive and negative populations were defined according to 1) a non-stained sample as negative control. 2) an HbF expressing cell as positive control. 3) an obvious separation of HbF+ and HbF- populations.

 \square Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.